The largest round in the field of epigenetic reprogramming — $435 million Series C — was closed by NewLimit in June 2026. Investors led by Founders Fund believed that it would be possible to restore youthful function to liver cells without changing their identity. First human trials are already scheduled for 2027.
The bet here is not just on another drug for a disease, but on an attempt to influence the very process of cellular aging. If the approach works, it could change the approach to age-related liver diseases and metabolic disorders that are currently treated symptomatically. However, between encouraging results in old human cells and mice and real benefit for patients lies a long path of regulatory scrutiny and clinical data.
The company was founded in 2021 by Brian Armstrong from Coinbase, Blake Byers, and Jacob Kimmel, who became CEO. NewLimit uses artificial intelligence and genomic technologies to select transcription factors capable of "rejuvenating" the cell's epigenome. The lead program is an mRNA therapy in lipid nanoparticles, specifically targeting hepatocytes. According to the press release, in preclinical studies the therapy restored liver regeneration in old mice and increased resistance to alcohol-induced damage.
Compared to other players, NewLimit stands out for its narrow focus on the liver and accelerated timeline. Life Biosciences, for example, is developing partial reprogramming for ophthalmology and also plans clinical trials, but at later stages. Retro Biosciences works with autophagy and cell therapies. The overall trend is clear: capital is actively flowing into reprogramming, but most projects still rely on preliminary in vitro and animal model data.
Imagine a liver cell as an old engine in which dust has accumulated in the settings: transcription factors act like a targeted cleaning, restoring original parameters without replacing the entire mechanism. That is how the mechanism is described in the company — without changing the cell type, only restoring youthful function. This sounds elegant, but in practice it remains to be proven that the effect will persist in the human body and will not cause unforeseen consequences.
Funding of this scale reflects not only scientific optimism but also commercial interest: a successful therapy for liver aging opens a market measured in tens of billions. At the same time, investors, including Eli Lilly Ventures, are clearly factoring in risks — from regulatory hurdles to the possible lack of long-term efficacy in humans.
The appearance of the first such program in the clinic in 2027 will show how plastic aging is at the epigenome level and where the real boundaries of this approach lie.
